CAS: 61869-08-7; (3S,4R)-3-((Benzo[d][1,3]Dioxol-5-Yloxy)Methyl)-4-(4-Fluorophenyl)Piperidine

英文名称(3S,4R)-3-((Benzo[d][1,3]Dioxol-5-Yloxy)Methyl)-4-(4-Fluorophenyl)Piperidine
中文名称帕罗西汀
IUPAC名称(3S,4R)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
其它别名(3S,4R)-3-[(1,3-Benzodioxol-5-Yloxy)Methyl]-4-(4-Fluorophenyl)Piperidine; (-)-Trans-4-(P-Fluorophenyl)-3-[[3,4-(Methylenedioxy)Phenoxy]Methyl]-Piperidine; (+/-)-Paroxetine; Casbol; N06Ab05; Paroxetina (Inn-Spanish)
CAS编号61869-08-7
MFCD编号:MFCD00869588
EINECS号:682-717-4
分子式:C19H20FNO3
分子量:329.37
产品CID: 1600668
同类组份化合物CAS61869-08-7 (free base)64006-44-6 (maleate)78246-49-8 (HCl)72471-80-8 (acetate)217797-14-3 (mesylate)110429-35-1 (HCl hydrate)
产品分类原料药 → 神经系统用药 → 抗抑郁、躁狂药

相似结构搜索
InChIKey: AHOUBRCZNHFOSL-YOEHRIQHSA-N
InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1…
计算化学: 氢键受体数5.0氢键供体数1.0可旋转键数4.0

物理性质

熔点114-116 °C
沸点451.7±45.0 °C at 760 mmHg
闪点227.0±28.7 °C
密度1.2±0.1 g/cm3
pKa:pKa 9.51 (Uncertain)
PSA:39.72
LogP:3.89
折射率1.561
蒸汽压0.0±1.1 mmHg at 25°C
溶解性In water, 1,131 mg/L at 25 °C
敏感性盐酸帕罗西汀(Paroxetine Hydroehloride)：C19H20FNO3.HCI。微小片状结晶，熔点118°C。盐酸帕罗西汀半水合物(Paroxetine Hydr°Chloride Hemihydrate)：C19H20FN03.HCI.1/2H2O。结晶，熔点129～131°C。马来酸帕罗西汀(Paroxetine Maleate)：C19H20FNO3.C4H4O4。从乙醇-乙醚结晶，熔点136～138°C。[α]D-87°(C=5，乙醇)。急性毒性LD50小鼠(mg/kg)：845皮下注射，500口服。
外观形态类白色至淡黄色固体
储存条件在惰性气体(氮气或氩气)下 2–8 °C
产品应用帕罗西汀(61869-08-7)的用途:该药能强力和选择性地抑制突触体对5-羟色胺的重吸收,不直接干扰任何中枢神经递质受体.用于抑郁,特别是焦虑和强迫症.
性质描述帕罗西汀(61869-08-7)的性状:1.盐酸帕罗西汀(Paroxetine Hydr°Chloride):C19H20FNO3・HCl,微小片状结晶,熔点118°C.2.盐酸帕罗西汀半水合物(Paroxetine Hydr°Chloride Hemihydrate):C19H20FNO3・HCl・1/2H2O,结晶,熔点129～131°C.3.马来酸帕罗西汀(Paroxetine Maleate):C19H20FNO3・C4H4O4,从乙醇-乙醚结晶,熔点136～138°C.[α]D－87°(c=5,乙醇).急性毒性LD50小鼠(mg/kg):845皮下注射,500口服.

MSDS等安全信息

GHS象形图
GHS符号GHS08 & GHS07 & GHS09;
注释: Health hazard & Exclamation mark & Environment
危险类别生殖毒性类别1A
急性毒性类别4(经口)
水生慢性毒性类别1
警示词Danger(危险)
危险描述H360 |可能损害生育能力或胎儿.
H302 |吞咽有害.
H410 |对水生生物毒性极大并具有长期持续影响.
防范说明P261-P305+P351+P338
危险等级6.1(b)
UN编号3249
危险品标志Xi
包装等级III
安全声明IDENTIFICATION AND USE: Paroxetine is an odorless off-white powder formulated into an oral suspension, extended-release film-coated tablets, or film-coated tablets. Paroxetine a second generation selective serotonin-reuptake inhibitor is used for the treatment of major depressive disorder, obsessive and compulsive disorder, panic disorder, social anxiety disorders, general anxiety disorders, and posttraumatic stress disorder. Paroxetine has more recently been approved for use in the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. HUMAN EXPOSURE AND TOXICITY: Spontaneous cases of deliberate or accidental overdosage during paroxetine treatment have been reported; some of these cases were fatal and some of the fatalities appeared to involve paroxetine alone. Commonly reported adverse reactions associated with paroxetine overdosage include somnolence, coma, nausea, tremor, tachycardia, confusion, vomiting, and dizziness. Other notable signs and symptoms observed with overdoses involving paroxetine (alone or with other substances) include mydriasis, convulsions (including status epilepticus), ventricular dysrhythmias (including torsades de pointes), hypertension, aggressive reactions, syncope, hypotension, stupor, bradycardia, dystonia, rhabdomyolysis, symptoms of hepatic dysfunction (hepatic failure, hepatic necrosis, jaundice, hepatitis, and hepatic steatosis), serotonin syndrome, manic reactions, myoclonus, acute renal failure, and urinary retention. During premarketing testing, seizures occurred in 0.1% of patients treated with paroxetine. During premarketing testing, hypomania or mania occurred in approximately 1.0% of paroxetine-treated unipolar patients. In a subset of patients classified as bipolar, the rate of manic episodes was 2.2% for paroxetine and 11.6% for the combined active-control groups. Stevens-Johnson syndrome and toxic epidermal necrolysis have also been reported in paroxetine-treated patients. Epidemiological studies have shown that infants exposed to paroxetine in the first trimester of pregnancy have an increased risk of congenital malformations, particularly cardiovascular malformations. Perinatal adverse effects, including respiratory distress and neonatal adaptation problems are common in exposed infants, and an increased risk for persistent pulmonary hypertension of the newborn (PPHN) has been observed. Also, some neonates exposed to paroxetine and other selective serotonin-reuptake inhibitors (SSRIs) or selective serotonin- and norepinephrine-reuptake inhibitors (SNRIs) late in the third trimester of pregnancy have developed complications that occasionally have been severe and required prolonged hospitalization, respiratory support, enteral nutrition, and other forms of supportive care in special care nurseries. Clinical findings reported to date in the neonates have included respiratory distress, cyanosis, apnea, seizures, temperature instability or fever, feeding difficulty, dehydration, excessive weight loss, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, lethargy, reduced or lack of reaction to pain stimuli, and constant crying. Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Genotoxicity tests for cytogenetic aberrations in vitro in human lymphocytes were negative. ANIMAL STUDIES: Two-year carcinogenicity studies were conducted in rodents given paroxetine in the diet at 1, 5, and 25 mg/kg/day (mice) and 1, 5, and 20 mg/kg/day (rats). There was a significantly greater number of male rats in the high-dose group with reticulum cell sarcomas (1/100, 0/50, 0/50, and 4/50 for control, low-, middle-, and high-dose groups, respectively) and a significantly increased linear trend across dose groups for the occurrence of lymphoreticular tumors in male rats. Female rats were not affected. Although there was a dose-related increase in the number of tumors in mice, there was no drug-related increase in the number of mice with tumors. The relevance of these findings to humans is unknown. Reproduction studies in rats receiving oral paroxetine dosages of 50 mg/kg daily and in rabbits receiving 6 mg/kg daily during organogenesis have been conducted. Although these studies have not revealed evidence of teratogenicity, an increase in pup deaths was observed in rats during the first 4 days of lactation when dosing occurred during the last trimester of gestation and continued throughout lactation. This effect occurred at a dose of 1 mg/kg daily. A reduced pregnancy rate was found in reproduction studies in rats at a dose of paroxetine of 15 mg/kg/day. Irreversible lesions occurred in the reproductive tract of male rats after dosing in toxicity studies for 2 to 52 weeks. These lesions consisted of vacuolation of epididymal tubular epithelium at 50 mg/kg/day and atrophic changes in the seminiferous tubules of the testes with arrested spermatogenesis at 25 mg/kg/day. Paroxetine produced no genotoxic effects in a battery of in vitro and in vivo assays that included the following: Bacterial mutation assay, mouse lymphoma mutation assay, unscheduled DNA synthesis assay, and tests for cytogenetic aberrations in vivo in mouse bone marrow and in a dominant lethal test in rats. | Though it is rarely lethal in overdose by itself, patients can develop somnolence, nausea, tremor, heart rhythm disturbances, confusion, vomiting, dizziness, and mydriasis. During toxicity, a patient’s airway, oxygenation, and ventilation require evaluation first. The treatment for overdose includes symptomatic supportive treatment. There is no specific treatment for paroxetine toxicity. | Paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake. Paroxetine likely inhibits the reuptake of serotonin at the neuronal membrane, enhances serotonergic neurotransmission by reducing turnover of the neurotransmitter, therefore it prolongs its activity at synaptic receptor sites and potentiates 5-HT in the CNS; paroxetine is more potent than both sertraline and fluoxetine in its ability to inhibit 5-HT reuptake. Compared to the tricyclic antidepressants, SSRIs have dramatically decreased binding to histamine, acetylcholine, and norepinephrine receptors. The mechanism of action for the treatment of vasomotor symptoms is unknown.

欧盟法规

ECHA物质C&L通报

上下游产品

合成工艺路线路线简述

1-(4-Fluorophenyl)-3-(4-Methoxyphenylamino)Propan-1-One置于2-甲基-2-丁醇甲醇,Sodium Hydroxide,Ammonium Cerium(Iv) Nitrate,硼烷,Sodium Ethanolate,Sodium Hydride,Sodium Carbonate,Caesium Carbonate,(+/-)-2,2 '-二(二-对甲苯基膦)-1,1 '-联萘,三氟乙酸,Copper Dichloride,Sodium T-Butanolate体系中,用四氢呋喃,氟苯,乙醇,二氯甲烷,邻二甲苯,水,甲苯,乙腈作为反应溶剂,化学反应 47.5H,反应生成帕罗西汀
参考文献:内酯和内酰胺的催化对映选择性共轭还原
标题:内酯和内酰胺的催化对映选择性共轭还原
摘要:据报道,在添加醇添加剂后,α,β-不饱和内酯,内酰胺和酯的对映选择性铜催化共轭还原显着加速.使用由 Cucl(2).H(2)O,T-Buona,P-Tol-Binap 和 Pmhs 原位反应生成的催化剂实现了非常好到优异的产率和对映选择性,并且该方法用于合成 (-)-帕罗西汀.
DOI:10.1021/ja0351692

海关参考信息

2902600000-乙苯
2902700000-异丙基苯
2905121000-正丙醇
2907210001-间苯二酚
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

其他信息查阅

浙江九洲药业股份有限公司

网址: http://www.jiuzhoupharma.com
电话: 0576-88827561👤

⚠️ 未注册 · 未认证企业

备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议，请通过页面底部联系方式告知我们，我们会尽快处理。

台州开创生物医药有限公司

网址: http://www.creatingbiopharm.com
企业联系电话：0576-88827176;18906581668👤
地址:浙江省台州市君悦大厦A幢715

⚠️ 未注册 · 未认证企业

备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议，请通过页面底部联系方式告知我们，我们会尽快处理。

北京诺德恒信化工技术有限公司

网址: http://www.nordhuns.com
电话: 010-84929330👤

⚠️ 未注册 · 未认证企业

南京齐达国际贸易有限公司

网址: http://www.qidachemical.com
电话: 86-025-86460031👤

⚠️ 未注册 · 未认证企业

浙江华伟医药科技有限公司

网址: http://www.hwasunpharm.com
企业联系电话：0576-88517043👤
地址:浙江台州市椒江区岩头工业区

⚠️ 未注册 · 未认证企业

备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议，请通过页面底部联系方式告知我们，我们会尽快处理。

第 1 / 1 页

现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献

1: Wang Y, Zhang A, Dilinuer A, Hao L, Hu Z, Jia W. Meta-analysis of acupuncture combined with paroxetine in the treatment of depression. Am J Transl Res. 2022 Dec 15;14(12):8429-8436.
2: Zeng M, Gong A, Wu Z. Paroxetine combined with traditional chinese medicine prescriptions in the treatment of postpartum depression: A systematic review of randomized controlled trials. Front Neuroendocrinol. 2022 Oct;67:101019. doi: 10.1016/j.yfrne.2022.101019. Epub 2022 Aug 1. 2006–. Paroxetine. 2022 May 15.
14:353-361. doi: 10.2147/IJWH.S282396.